LEO Pharma Acquires Timber Pharmaceuticals (TMB-001) in Up to $36 Million Deal
August 21, 2023
LEO Pharma signed an agreement to acquire U.S.-listed Timber Pharmaceuticals in a deal valued at up to $36 million. The transaction will add Timber’s late-stage dermatology asset, TMB-001 (topical reformulation of isotretinoin for congenital ichthyosis), to LEO Pharma’s pipeline; closing is expected in Q4 2023, subject to shareholder approval and other conditions.
- Buyers
- LEO Pharma
- Targets
- Timber Pharmaceuticals
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
BioPharmX Corp to Merge with Timber Pharmaceuticals
January 28, 2020
Pharmaceuticals
BioPharmX Corporation (NYSE American: BPMX) entered into a definitive merger agreement with Timber Pharmaceuticals LLC whereby a BioPharmX subsidiary will merge into Timber, leaving Timber as a wholly‑owned subsidiary of BioPharmX. The transaction will bring at least $20 million of financing to the combined company, after which BioPharmX will change its name to Timber Pharmaceuticals and Timber’s management will become the combined company's leadership.
-
Takeda Acquires Nimbus Therapeutics' TYK2 Program Subsidiary (Nimbus Lakshmi)
February 8, 2023
Pharmaceuticals
Takeda Pharmaceutical Company Limited has completed the acquisition of all shares of Nimbus Lakshmi, Inc. (the TYK2 program subsidiary of Nimbus Therapeutics) for approximately $4.0 billion upfront, with up to $2.0 billion in potential milestone payments. The deal adds TAK-279 (NDI-034858), a selective oral TYK2 inhibitor moving into late‑stage development, strengthening Takeda's late‑stage pipeline in immune‑mediated diseases including psoriasis and other immunological indications.
-
Otsuka Pharmaceutical Acquires Transcend Therapeutics
March 27, 2026
Biotechnology
Otsuka Pharmaceutical entered into an agreement to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion. Under the terms, Otsuka will pay $700 million upfront at closing and up to $525 million in contingent payments tied to future sales milestones, with expected closing in Q2 2026.
-
Star Equity Holdings Acquires Timber Technologies
May 17, 2024
Building Products
Star Equity Holdings, Inc. completed the acquisition of Timber Technologies, LLC (Timber Tech), a Colfax, Wisconsin-based glue-laminated timber (glulam) manufacturer, effective May 17, 2024. The cash-free, debt-free purchase price was $23 million (including upfront cash, deferred cash and an earn-out), with associated real estate to be acquired separately for $3 million; Timber Tech reported 2023 revenue of $18.8 million and Adjusted EBITDA of $5.5 million.
-
Bristol Myers Squibb Acquires Turning Point Therapeutics
June 3, 2022
Healthcare Services
Bristol Myers Squibb will acquire Turning Point Therapeutics in a $4.1 billion, all-cash transaction at $76.00 per share under a definitive merger agreement. The deal was originally expected to close in Q3 2022, and the acquisition was completed in August 2022.
-
Iptor Acquires TimberTec
February 1, 2022
Software
Stockholm-based Iptor acquired German TimberTec, a provider of ERP and MES software for the timber industry, in a deal that closed in February 2022. The acquisition is an add-on in Iptor's buy-and-build strategy (backed by funds advised by Bregal Unternehmerkapital) and aims to expand Iptor’s sector capabilities and geographic reach across Europe and into the US.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.